Status:
RECRUITING
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
NSCLC
IMMUNOTHERAPY
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Non-small cell lung cancer (NSCLC) is a major public health problem. New treatments as immunotherapy can improve prognosis of patients with NCLC tumors. Nevertheless, no robust biomarker is actually a...
Eligibility Criteria
Inclusion
- age over 18
- informed of the objectives of the project and signed consent
- non small cell lung cancer, stage IIIA, IIIB or IV
- PS (WHO performance status) \< or =2
- treatment based on immunotherapy (monotherapy or combination)
- at least one measurable target
- available results of PD-L1 expression
Exclusion
- concomitant other type of cancer
- another cancer in the last 5 years
Key Trial Info
Start Date :
May 27 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 27 2027
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04720339
Start Date
May 27 2021
End Date
October 27 2027
Last Update
November 23 2022
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Besancon - Service de pneumologie
Besançon, France
2
Hopitaux Civils de Colmar - service de Pneumologie
Colmar, France
3
CHU de Dijon - service de Pneumologie
Dijon, France
4
CLCC Georges-François Leclerc
Dijon, France